Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Voyager Therapeutics, Inc. (VYGR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 4 PFREUNDSCHUH PETER P. (CFO) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Sold 13,567 shares @ $6.99, valued at $94.8k
10/03/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 4 Fahey Sandell Jacquelyn (Chief Legal Officer) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 61,000 shares @ $0
08/16/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "First Amendment to Lease Agreement, by and between Voyager Therapeutics, Inc. and LS 75 Hayden, LLC"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
07/11/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/11/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/10/2023 4 Carter Todd Alfred (Chief Scientific Officer) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Sold 5,500 shares @ $10.8, valued at $59.4k
07/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EMPLOYMENT AGREEMENT This Employment Agreement is made as of July 5, 2023 by and between Voyager Therapeutics, Inc. and Jacquelyn Fahey Sandell . 1.             Employment . The Company and the Executive desire that the Executive be employed as the Company’ s Chief Legal Officer. The employment relationship between the Company and the Executive shall be governed by this Agreement, with the Executive’ s first day of employment commencing as of a date mutually agreed upon by the Company and the Executive, but in no event later than July 10, 2023 , and continuing in effect until terminated by either party in accordance with this Agreement. At all times, the Executive’ s employment with the Company will be “at-will,” meani..."
07/06/2023 144 Form 144 - Report of proposed sale of securities:
07/05/2023 4 Carter Todd Alfred (Chief Scientific Officer) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Sold 5,000 shares @ $11.41, valued at $57.1k
Exercised 5,000 options to buy @ $2.85, valued at $14.3k
06/30/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 4 PIERCE GLENN (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 4 MACKEY CATHERINE J (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 4 Vitale Nancy (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 4 Onyia Jude (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 4 Higgins Michael J (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 4 Colon Grace (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 4 GERAGHTY JAMES A (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 4 SCANGOS GEORGE A (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 4 Hyman Steven (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 22,000 options to buy @ $12.57, valued at $276.5k
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 4 SCANGOS GEORGE A (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Granted 44,000 options to buy @ $10.76, valued at $473.4k
05/11/2023 3 SCANGOS GEORGE A (Director) has filed a Form 3 on Voyager Therapeutics, Inc.
05/09/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
05/09/2023 8-K Appointed a new director
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2023 4 Sandrock Alfred (President and CEO) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Sold 7,437 shares @ $7.83, valued at $58.2k
04/05/2023 4 Swartz Robin (COO) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns: Sold 1,259 shares @ $7.83, valued at $9.9k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy